Shares of bluebird bio (NASDAQ: BLUE) were down in pre-market trading on Monday after the biotechnology company stated in an SEC filing that it had appointed Katherine Breedis as the Company’s interim CFO, its principal financial officer, and principal accounting officer.
Breedis will succeed Jason F. Cole, bluebird bio’s current Chief Strategy and Financial Officer. Breedis’s appointment will be effective from October 14, 2022.
